MEDIA CENTER - 2017 - 2018

May 25th, 2018
APIM Therapeutics has submitted a formal application for clinical trial approval in Australia for ATX-101. The application will allow the company to initiate a multicenter, first-in-man phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of ATX-101 in patients with advanced solid tumors. A copy of the relevant press release is available here.

February 26, 2018
Oncotarget publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper shows that ATX-101 improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. A copy of the publication is available here.

December 1, 2017
APIM Therapeutics has announced that the company has closed a Financing round raising 25 mNOK (3 m$). Funds will be used to file a Clinical Trial Application (CTA) and start the clinical development program of APIM Therapeutics’ anti-cancer lead compound, ATX-101. A copy of the press release is available here.

March 6, 2017
APIM Therapeutics will be participating at BioEurope Spring Partnering meeting, in Barcelona, pain (March 20-22, 2017).

Visit Media Center 2015 & 2016
Visit Media Center 2013 & 2014
Visit Media Center 2012
Visit Media Center 2010 & 2011

To learn more the APIM-motif, ATX-101 and PCNA, please see attached the publications (given as pdf files):

1. Gilljam KM et al, 2009. Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol 186, pp645-654.

2. Müller R et al, 2013. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7).

3. Baglo Y et al, 2014. Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization. Biomed Res Int. 2014;2014:921296.

4. Gederaas OA et al, 2014. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014 Dec;7(6):812-23.

5. Olaisen C et al, 2014. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 2015 Jul;27(7):1478-87.

6. Søgaard K et al, 2018. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. Oncotarget. 2018; 9:11752-11766.

The following posters presented in TAT and AACR 2016 meetings provide latest efficacy data in bladder and breast cancer models as well as genomic and kinomic analysis conducted in these tumors:

7. Poster presented in the 14th International Congress on Targeted Anticancer Therapies.

8. Poster presented in the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer. 

For an excellent review discussing the druggability of PCNA and ATX-101:

9. Wang Shao-Chun, 2014. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014 Apr;35(4):178-186.



APIM Therapeutics AS is a spin-off from the Norwegian University of Science and Technology (NTNU).

Visit our About Us page to find out more.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit to find out more.